A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Subjects
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Soticlestat (Primary)
- Indications Complex regional pain syndromes; Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Myoclonic epilepsies; Tuberous sclerosis
- Focus Adverse reactions
- Sponsors Takeda
- 16 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI205349).
- 29 Nov 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2020 Status changed from recruiting to active, no longer recruiting.